This company has been marked as potentially delisted and may not be actively trading. Seneca Biopharma (SNCA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock SNCA vs. ATRA, IPSC, BLUE, QNCX, ARTV, SCLX, ALGS, PLUR, COEP, and ESLAShould you be buying Seneca Biopharma stock or one of its competitors? The main competitors of Seneca Biopharma include Atara Biotherapeutics (ATRA), Century Therapeutics (IPSC), bluebird bio (BLUE), Quince Therapeutics (QNCX), Artiva Biotherapeutics (ARTV), Scilex (SCLX), Aligos Therapeutics (ALGS), Pluri (PLUR), Coeptis Therapeutics (COEP), and Estrella Immunopharma (ESLA). These companies are all part of the "medical" sector. Seneca Biopharma vs. Its Competitors Atara Biotherapeutics Century Therapeutics bluebird bio Quince Therapeutics Artiva Biotherapeutics Scilex Aligos Therapeutics Pluri Coeptis Therapeutics Estrella Immunopharma Atara Biotherapeutics (NASDAQ:ATRA) and Seneca Biopharma (NASDAQ:SNCA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, community ranking, institutional ownership, valuation, earnings, risk, profitability and dividends. Which has higher earnings & valuation, ATRA or SNCA? Seneca Biopharma has lower revenue, but higher earnings than Atara Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtara Biotherapeutics$199.73M0.26-$276.13M-$3.72-2.31Seneca Biopharma$10K1,107.12-$8.35MN/AN/A Do analysts recommend ATRA or SNCA? Atara Biotherapeutics currently has a consensus price target of $17.75, suggesting a potential upside of 106.88%. Given Atara Biotherapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Atara Biotherapeutics is more favorable than Seneca Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atara Biotherapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.57Seneca Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community favor ATRA or SNCA? Atara Biotherapeutics received 423 more outperform votes than Seneca Biopharma when rated by MarketBeat users. Likewise, 67.33% of users gave Atara Biotherapeutics an outperform vote while only 63.64% of users gave Seneca Biopharma an outperform vote. CompanyUnderperformOutperformAtara BiotherapeuticsOutperform Votes43767.33% Underperform Votes21232.67% Seneca BiopharmaOutperform Votes1463.64% Underperform Votes836.36% Which has more volatility & risk, ATRA or SNCA? Atara Biotherapeutics has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500. Comparatively, Seneca Biopharma has a beta of 1.83, indicating that its share price is 83% more volatile than the S&P 500. Does the media favor ATRA or SNCA? In the previous week, Atara Biotherapeutics had 2 more articles in the media than Seneca Biopharma. MarketBeat recorded 2 mentions for Atara Biotherapeutics and 0 mentions for Seneca Biopharma. Atara Biotherapeutics' average media sentiment score of 1.78 beat Seneca Biopharma's score of 0.00 indicating that Atara Biotherapeutics is being referred to more favorably in the media. Company Overall Sentiment Atara Biotherapeutics Very Positive Seneca Biopharma Neutral Is ATRA or SNCA more profitable? Atara Biotherapeutics has a net margin of -132.58% compared to Seneca Biopharma's net margin of -230.34%. Atara Biotherapeutics' return on equity of 0.00% beat Seneca Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Atara Biotherapeutics-132.58% N/A -90.16% Seneca Biopharma -230.34%-122.20%-110.61% Do insiders & institutionals have more ownership in ATRA or SNCA? 70.9% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 5.2% of Seneca Biopharma shares are owned by institutional investors. 4.0% of Atara Biotherapeutics shares are owned by company insiders. Comparatively, 2.1% of Seneca Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryAtara Biotherapeutics beats Seneca Biopharma on 14 of the 17 factors compared between the two stocks. Get Seneca Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for SNCA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNCA vs. The Competition Export to ExcelMetricSeneca BiopharmaBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.07M$3.08B$5.52B$8.63BDividend YieldN/A1.54%5.27%4.17%P/E RatioN/A31.8426.6019.77Price / Sales1,107.12458.05404.62150.29Price / CashN/A168.6838.2534.64Price / Book0.483.367.074.68Net Income-$8.35M-$72.17M$3.21B$247.80M Seneca Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNCASeneca BiopharmaN/A$0.64-7.2%N/A-86.2%$11.07M$10K0.007Gap DownATRAAtara Biotherapeutics4.4709 of 5 stars$8.35-0.5%$17.75+112.6%-31.0%$49.63M$199.73M-0.32330Positive NewsGap UpIPSCCentury Therapeutics2.4807 of 5 stars$0.570.0%$4.20+636.8%-81.6%$49.02M$114.90M-0.31170Gap UpBLUEbluebird bio3.0363 of 5 stars$4.97flat$44.60+797.4%N/A$48.67M$103.95M-0.13520QNCXQuince Therapeutics3.6579 of 5 stars$1.07+1.9%$8.00+647.7%+101.4%$48.65MN/A-0.8660Analyst ForecastARTVArtiva Biotherapeutics2.605 of 5 stars$1.97+1.0%$19.40+884.8%N/A$48.00M$251K0.0081News CoveragePositive NewsUpcoming EarningsAnalyst RevisionGap UpSCLXScilex2.3691 of 5 stars$6.45+17.9%$455.00+6,954.3%-91.4%$43.93M$50.71M-7.6180Positive NewsALGSAligos Therapeutics4.4442 of 5 stars$6.38+7.2%$70.00+997.4%-38.3%$39.09M$3.27M-0.4890Gap UpPLURPluri2.2769 of 5 stars$4.43-3.3%$12.00+170.9%-19.4%$34.70M$1.03M-0.79150Short Interest ↑Gap UpCOEPCoeptis Therapeutics1.3656 of 5 stars$9.49-0.5%N/A+27.1%$33.35M$62.87K-1.642Positive NewsESLAEstrella Immunopharma2.0958 of 5 stars$0.91+8.7%$16.00+1,664.1%+2.1%$32.80MN/A-3.49N/A Related Companies and Tools Related Companies Atara Biotherapeutics Alternatives Century Therapeutics Alternatives bluebird bio Alternatives Quince Therapeutics Alternatives Artiva Biotherapeutics Alternatives Scilex Alternatives Aligos Therapeutics Alternatives Pluri Alternatives Coeptis Therapeutics Alternatives Estrella Immunopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNCA) was last updated on 6/16/2025 by MarketBeat.com Staff From Our PartnersAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBREAKING: Trump vs. Elon Feud Threatens Your Retirement – Protect Yourself NOW"This isn't just a war of words. This is a financial time bomb. The escalating battle between Donald Trump a...American Alternative | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. Chinese AI chatbot DeepSeek turned the tech world on its hea...Weiss Ratings | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seneca Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seneca Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SNCA Stock Free SNCA Stock Alerts